MétaCan
Menu
Back to cohort
Record W2078479971 · doi:10.1007/s12079-012-0172-4

Immunosuppression for interstitial lung disease in systemic sclerosis – novel insights and opportunities for translational research

2012· article· en· W2078479971 on OpenAlexafffund
Marie Hudson, Russell Steele, Murray Baron

Bibliographic record

VenueJournal of Cell Communication and Signaling · 2012
Typearticle
Languageen
FieldMedicine
TopicSystemic Sclerosis and Related Diseases
Canadian institutionsMcGill UniversityJewish General Hospital
FundersActelion PharmaceuticalsCanadian Institutes of Health ResearchPfizer
KeywordsInterstitial lung diseaseImmunosuppressionMedicineTranslational researchDiseaseLungScleroderma (fungus)Translational medicineIntensive care medicineBioinformaticsImmunologyPathologyBiologyInternal medicine

Abstract

fetched live from OpenAlex

Systemic sclerosis (SSc) is a chronic inflammatory disorder characterized by a disturbance in fibroblast function culminating in the telltale skin thickening and fibrosis of visceral organs.Interstitial lung disease (ILD) is common (Steele et al. 2011) and is the leading cause of death in this disease (Steen and Medsger 2007).The immunohistopathogenesis of SSc-ILD is characterized by immune dysfunction and inflammation.Thus, immunosuppression has been hypothesized as a useful treatment for SSc-ILD.However, randomized clinical trials (RCTs) have thus far only revealed a modest effect of immunosuppression (Hoyles et al. 2006;Tashkin et al. 2006).We believe that these small observed effects are due, at least in part, to the actual design of the RCTs, in particular subject selection, which did not properly identify patients likely to respond to treatment.SSc is an uncommon disease, with an estimated prevalence ranging from 7-489/million and incidence from 0.6-122/million/year (Chifflot et al. 2008).This rarity has undoubtedly contributed to the paucity of RCTs examining the benefit of immunosuppression in this disease.To date, only cyclophosphamide and azathioprine have been evaluated in RCTs of subjects with SSc-ILD.In the Scleroderma Lung Study (N0158) (Tashkin et al. 2006), SSc-ILD subjects with less than 7 years of disease duration who had not previously received cyclophosphamide were randomized to oral cyclophosphamide or placebo for 1 year.Those treated with cyclophosphamide had a smaller decline than those on placebo in forced vital capacity (FVC) (adjusted difference of 2.5 % [95 % CI 0.3, 4.8 %, p 00.03] favouring cyclophosphamide).In the Fibrosing Alveolitis in Scleroderma Trial (FAST; N045) (Hoyles et al. 2006), SSc-ILD subjects with an average of 5 years of disease who had not been previously treated were randomized to receive 6 monthly infusions of cyclophosphamide followed by 6 months of oral daily azathioprine, or placebo.Although not statistically significant, the adjusted between-group difference in FVC of 4.2 % showed a strong trend in favour of the treated group (95 % CI -0.57, 8.95, p0 0.08).Mycophenolate mofetil (MMF) is a third immunosuppressant that is currently being tested in an ongoing RCT in subjects with SSc-ILD (Scleroderma Lung Study II http://

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.011
Threshold uncertainty score0.061

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0110.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.002
Science and technology studies0.0010.002
Scholarly communication0.0030.007
Open science0.0020.001
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.197
GPT teacher head0.357
Teacher spread0.161 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2012
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Cell Communication and SignalingSame topicSystemic Sclerosis and Related DiseasesFrench-language works237,207